1. Home
  2. JYNT vs EQ Comparison

JYNT vs EQ Comparison

Compare JYNT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$9.17

Market Cap

117.3M

Sector

Miscellaneous

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$2.83

Market Cap

129.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYNT
EQ
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.3M
129.0M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
JYNT
EQ
Price
$9.17
$2.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$17.00
$8.00
AVG Volume (30 Days)
69.0K
354.7K
Earning Date
05-07-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
133.93
N/A
EPS
0.09
N/A
Revenue
$117,696,356.00
$41,095,000.00
Revenue This Year
$12.23
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$102.44
N/A
Revenue Growth
15.49
N/A
52 Week Low
$7.50
$0.29
52 Week High
$13.47
$3.10

Technical Indicators

Market Signals
Indicator
JYNT
EQ
Relative Strength Index (RSI) 53.40 66.95
Support Level $8.49 $1.38
Resistance Level $9.33 N/A
Average True Range (ATR) 0.37 0.29
MACD 0.06 0.07
Stochastic Oscillator 58.90 80.67

Price Performance

Historical Comparison
JYNT
EQ

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: